Literature DB >> 12852233

Update on the biology and management of canine osteosarcoma.

Ruthanne Chun1, Louis-Philippe de Lorimier.   

Abstract

Osteosarcoma (OSA) is the most common primary bone tumor diagnosed in dogs. Our understanding of the risk factors and genetic changes in canine OSA patients is growing, but specific, innovative therapeutic strategies are slow in coming. Appendicular skeletal osteosarcoma, the most frequent form of this disease, is typically seen in large to giant breeds, with males being overrepresented in most reports. Axial skeletal OSA is less common than appendicular OSA, but the biologic behavior of the disease is equally aggressive in all skeletal sites except for the mandible. Though the current standard of care for dogs with osteosarcoma remains surgical resection of the affected site, followed by chemotherapy with either a platinum- (cisplatin or carboplatin) or doxorubicin-based protocol, novel therapies are being actively investigated.

Entities:  

Mesh:

Year:  2003        PMID: 12852233     DOI: 10.1016/s0195-5616(03)00021-4

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  17 in total

1.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.

Authors:  Melissa Paoloni; Sean Davis; Susan Lana; Stephen Withrow; Luca Sangiorgi; Piero Picci; Stephen Hewitt; Timothy Triche; Paul Meltzer; Chand Khanna
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

2.  Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.

Authors:  Tobie D Wolfe; Smitha Pankajavally Somanathan Pillai; Blake Eason Hildreth; Lisa G Lanigan; Chelsea K Martin; Jillian L Werbeck; Thomas J Rosol
Journal:  Clin Exp Metastasis       Date:  2011-03-04       Impact factor: 5.150

3.  Met interacts with EGFR and Ron in canine osteosarcoma.

Authors:  J K McCleese; M D Bear; S K Kulp; C Mazcko; C Khanna; C A London
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

4.  Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997-2008).

Authors:  William T N Culp; Francisco Olea-Popelka; Jennifer Sefton; Charles F Aldridge; Stephen J Withrow; Mary H Lafferty; Robert B Rebhun; Michael S Kent; Nicole Ehrhart
Journal:  J Am Vet Med Assoc       Date:  2014-11-15       Impact factor: 1.936

5.  A clinically relevant mouse model of canine osteosarcoma with spontaneous metastasis.

Authors:  Beth K Chaffee; Matthew J Allen
Journal:  In Vivo       Date:  2013 Sep-Oct       Impact factor: 2.155

6.  Chondroblastic osteosarcoma of the middle ear in a guinea pig (Cavia porcellus).

Authors:  Ophélie Cojean; Isabelle Langlois; Magaly Bégin-Pépin; Pierre Hélie
Journal:  Can Vet J       Date:  2018-08       Impact factor: 1.008

7.  The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; Jiayuh Lin; Chenglong Li; Eric B Schwartz; Pui-Kai Li; James R Fuchs; Joelle Fenger; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2011-03-28       Impact factor: 4.430

8.  A specific role for phosphoinositide 3-kinase and AKT in osteoblasts?

Authors:  Imelda M McGonnell; Agamemnon E Grigoriadis; Eric W-F Lam; Joanna S Price; Andrew Sunters
Journal:  Front Endocrinol (Lausanne)       Date:  2012-07-20       Impact factor: 5.555

9.  Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor development.

Authors:  Amir-Shaya Sharili; Steve Allen; Ken Smith; Joanna Price; Imelda M McGonnell
Journal:  Cancer Lett       Date:  2013-01-22       Impact factor: 8.679

10.  Genomic instability and telomere fusion of canine osteosarcoma cells.

Authors:  Junko Maeda; Charles R Yurkon; Hiroshi Fujisawa; Masami Kaneko; Stefan C Genet; Erica J Roybal; Garrett W Rota; Ethan R Saffer; Barbara J Rose; William H Hanneman; Douglas H Thamm; Takamitsu A Kato
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.